203 related articles for article (PubMed ID: 21233244)
1. Epidemiology, natural history, and practice patterns of patients with myelodysplastic syndromes in 2010.
Sekeres MA
J Natl Compr Canc Netw; 2011 Jan; 9(1):57-63. PubMed ID: 21233244
[TBL] [Abstract][Full Text] [Related]
2. Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys.
Sekeres MA; Schoonen WM; Kantarjian H; List A; Fryzek J; Paquette R; Maciejewski JP
J Natl Cancer Inst; 2008 Nov; 100(21):1542-51. PubMed ID: 18957672
[TBL] [Abstract][Full Text] [Related]
3. The epidemiology of myelodysplastic syndromes.
Sekeres MA
Hematol Oncol Clin North Am; 2010 Apr; 24(2):287-94. PubMed ID: 20359626
[TBL] [Abstract][Full Text] [Related]
4. Patterns of erythropoiesis-stimulating agent use among Medicare beneficiaries with myelodysplastic syndromes and consistency with clinical guidelines.
Davidoff AJ; Weiss SR; Baer MR; Ke X; Hendrick F; Zeidan A; Gore SD
Leuk Res; 2013 Jun; 37(6):675-80. PubMed ID: 23523473
[TBL] [Abstract][Full Text] [Related]
5. Epidemiology of myelodysplastic syndromes: Why characterizing the beast is a prerequisite to taming it.
Zeidan AM; Shallis RM; Wang R; Davidoff A; Ma X
Blood Rev; 2019 Mar; 34():1-15. PubMed ID: 30314642
[TBL] [Abstract][Full Text] [Related]
6. Impact of transfusion on survival in patients with myelodysplastic syndromes: Current knowledge, new insights and transfusion clinical practice.
Kaphan E; Laurin D; Lafeuillade B; Drillat P; Park S
Blood Rev; 2020 May; 41():100649. PubMed ID: 31918886
[TBL] [Abstract][Full Text] [Related]
7. Effect of erythropoiesis-stimulating agent policy decisions on off-label use in myelodysplastic syndromes.
Hendrick F; Davidoff AJ; Zeidan AM; Gore SD; Baer MR
Medicare Medicaid Res Rev; 2014; 4(4):. PubMed ID: 25485173
[TBL] [Abstract][Full Text] [Related]
8. Managing patients with low-risk MDS.
Sekeres M; Cosgrove D; Falco A
Clin Adv Hematol Oncol; 2006 Jul; 4(7 Suppl 16):1-10; quiz 11-2. PubMed ID: 17139240
[TBL] [Abstract][Full Text] [Related]
9. Can iron overload in patients with lower-risk myelodysplastic syndromes be reduced using erythropoiesis-stimulating agents?
Tsang E; Leitch HA
Ann Hematol; 2016 Jan; 95(1):73-78. PubMed ID: 26453076
[TBL] [Abstract][Full Text] [Related]
10. Early treatment initiation in lower-risk myelodysplastic syndromes produces an earlier and higher rate of transfusion independence.
Cogle CR; Reddy SR; Chang E; Papoyan E; Broder MS; McGuire M; Binder G
Leuk Res; 2017 Sep; 60():123-128. PubMed ID: 28818807
[TBL] [Abstract][Full Text] [Related]
11. Increasing the effectiveness of hematopoiesis in myelodysplastic syndromes: erythropoiesis-stimulating agents and transforming growth factor-β superfamily inhibitors.
Mies A; Platzbecker U
Semin Hematol; 2017 Jul; 54(3):141-146. PubMed ID: 28958287
[TBL] [Abstract][Full Text] [Related]
12. Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q.
Nimer SD
J Clin Oncol; 2006 Jun; 24(16):2576-82. PubMed ID: 16735711
[TBL] [Abstract][Full Text] [Related]
13. Recent advances in low- and intermediate-1-risk myelodysplastic syndrome: developing a consensus for optimal therapy.
Stone R; Sekeres M; Garcia-Manero G; Lyons RM
Clin Adv Hematol Oncol; 2008 Dec; 6(12):1-15. PubMed ID: 19385003
[TBL] [Abstract][Full Text] [Related]
14. Myelodysplastic syndromes: incidence and survival in the United States.
Ma X; Does M; Raza A; Mayne ST
Cancer; 2007 Apr; 109(8):1536-42. PubMed ID: 17345612
[TBL] [Abstract][Full Text] [Related]
15. [CLINICAL AND EPIDEMIOLOGICAL CHARACTERISTICS OF MYELODYSPLASTIC SYNDROMES IN ADULTS].
Semochkin S; Tolstykh T; Dudina G; Fink O
Georgian Med News; 2016 Mar; (252):108-15. PubMed ID: 27119845
[TBL] [Abstract][Full Text] [Related]
16. Myelodysplastic syndromes: a practical approach to diagnosis and treatment.
Barzi A; Sekeres MA
Cleve Clin J Med; 2010 Jan; 77(1):37-44. PubMed ID: 20048028
[TBL] [Abstract][Full Text] [Related]
17. Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries.
Goldberg SL; Chen E; Corral M; Guo A; Mody-Patel N; Pecora AL; Laouri M
J Clin Oncol; 2010 Jun; 28(17):2847-52. PubMed ID: 20421543
[TBL] [Abstract][Full Text] [Related]
18. Myelodysplastic syndromes in the United States: an update for clinicians.
Troy JD; Atallah E; Geyer JT; Saber W
Ann Med; 2014 Aug; 46(5):283-9. PubMed ID: 24716735
[TBL] [Abstract][Full Text] [Related]
19. Myelodysplastic Syndromes in the Elderly: Treatment Options and Personalized Management.
Burgstaller S; Wiesinger P; Stauder R
Drugs Aging; 2015 Nov; 32(11):891-905. PubMed ID: 26476843
[TBL] [Abstract][Full Text] [Related]
20. Patient and physician perceptions about blood transfusions in the myelodysplastic syndromes.
King D; Schmidt R; Lesser M; Houk A; Salkeld E; Cogle CR
Leuk Res; 2020 Sep; 96():106425. PubMed ID: 32702549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
